INS and metabolic dysfunction-associated steatotic liver disease: Indeed, several studies have consistently shown that the MD significantly reduces NAFLD-related risks by improving lipid profiles, reducing hepatic fat content, enhancing insulin sensitivity, and decreasing intrahepatic fat and the characteristics and results of these relevant studies are shown in Table 1 [148–152].